The fastest path to regulatory-grade AI is rarely the one that starts from scratch — and rarely the one that hands over control. Here is how mature pharma organizations are doing both. The post The Build-vs-Buy Debate Is the Wrong One for Regulatory-Grade AI appeared first on Yseop .